You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Developing a novel adjuvant system for therapeutic vaccines against lung cancer

    SBC: FasCure Therapeutics LLC            Topic: 102

    DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Novel immunotherapy strategy for treatment of pancreatic cancer

    SBC: Oncotab, Inc.            Topic: NCI

    DESCRIPTION provided by applicant Pancreatic cancer has the worst prognosis of all cancers and is the fourth leading cause of cancer related deaths in the United States Patients usually present with advanced disease making curative attempts difficult Surgery is the only curative therapy since radiotherapy and chemotherapy remain largely ineffective coupled with undesirable side effects Desp ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Orally Bioavailable Gadolinium Chelators for Preventing and Ameliorating Toxicity Due to MRI Contrast Agents

    SBC: Capture Pharmaceuticals, Inc.            Topic: 102

    DESCRIPTION provided by applicant Capture Pharmaceuticals Inc is developing a drug called C E initially intended for treatment of individuals who have been contaminated by radioactive actinide elements following a nuclear terrorism event Because of the similarities between actinides and lanthanides it is expected that C E will also be effective in removing gadolinium Gd a lanthanide in ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Delivery of pathogen trapping antibodies for vaginal protection

    SBC: MUCOMMUNE, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Despite immense efforts in behavioral interventions to promote safer sexual practices sexually transmitted infections STIs continue to be a pandemic worldwide Unfortunately there are no effective vaccines or microbicides for the majority of STIs A pathogen specific safe effective and discreet vaginal microbicide that does not require daily or sex associ ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Small Molecule Antibiotic Potentiators for Drug-Resistant Bacteria

    SBC: AGILE SCIENCES, INC.            Topic: NIAID

    DESCRIPTION provided by applicant An estimated two million Americans suffer from infections caused by multi drug resistant MDR bacteria resulting in a substantial impact on patientsandapos lives and an extraordinary economic burden Due to the arsenal of antibiotic resistance mechanisms that these bacteria present traditional antibiotic therapies are often ineffective New strategies that u ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. CellRaft Array for Screening and Isolation of Highly Effective Cytotoxic T Cells

    SBC: Cell Microsystems, Inc.            Topic: NIAID

    PROJECT SUMMARY Cell Microsystems Inc is an early stage biotechnology company whose mission is the commercialization of a novel cost effective platform enabling the identification and efficient isolation of viable cells based on morphologic and fluorescence signatures as well as characteristics that change over time The CellRaft technology is based on a unique cell array recently developed ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. New Class of Bright Sharp Tunable Near Infrared Fluorophores for Flow Cytometry

    SBC: Nirvana Sciences, Inc.            Topic: R

    DESCRIPTION provided by applicant Polychromatic flow cytometry FC is one of the most powerful analytical techniques routinely used by both basic research and clinical diagnostics laboratories for the immunological categorization of cells Dyes used for FC typically exhibit broad fluorescent emission bands with full width at half maximum fwhm values of nm This limits the maximum numbe ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Human nasal epithelial organoids as a non-invasive, personalized model for predicting effectiveness of CFTR modulators in cystic fibrosis patients

    SBC: Path BioAnalytics, Inc.            Topic: ABC

    DESCRIPTION provided by applicant The discovery of the single gene CFTR cause of cystic fibrosis CF has been transformational focusing treatment on modulator drugs that restore function of the CFTR gene product CFTR andquot correctorsandquot enhance transport of mutant protein to the cell membrane and CFTR andquot potentiatesandquot activate mutant protein that does get to the membrane ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. The CellRaft AIR System Workflow Automation for Stem Cell Isolation and Recovery

    SBC: Cell Microsystems, Inc.            Topic: 200

    DESCRIPTION provided by applicant Stem cell research is an emerging field with the promise of creating dramatic new approaches for disease treatment and drug discovery The research and regenerative medicine market space for stem cells is one of the most dynamic areas in the life science industry today Globally the stem cell market is growing at a CAGR of and will reach an approximate ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Target Identification for Novel Small Molecule Therapeutic for Alzheimer's disease

    SBC: CoPlex Therapeutics, LLC            Topic: NIA

    ABSTRACT Traditional approaches to drug development for Alzheimer s disease are becoming increasingly expensive and in many cases disappointingly unsuccessful Based on preliminary in vitro and in vivo studies we have identified a novel small molecule methyl dimethyl oxo dihydrobenzo c naphthyridine carboxylate UK that significantly decreases A production and pro in ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government